GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apex Biotechnology Corp (TPE:1733) » Definitions » Cyclically Adjusted FCF per Share

Apex Biotechnology (TPE:1733) Cyclically Adjusted FCF per Share : NT$2.22 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Apex Biotechnology Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Apex Biotechnology's adjusted free cash flow per share for the three months ended in Mar. 2024 was NT$0.425. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$2.22 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Apex Biotechnology's average Cyclically Adjusted FCF Growth Rate was 13.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Apex Biotechnology was 0.20% per year. The lowest was -1.60% per year. And the median was -0.70% per year.

As of today (2024-06-02), Apex Biotechnology's current stock price is NT$33.45. Apex Biotechnology's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was NT$2.22. Apex Biotechnology's Cyclically Adjusted Price-to-FCF of today is 15.07.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Apex Biotechnology was 18.66. The lowest was 8.21. And the median was 12.18.


Apex Biotechnology Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Apex Biotechnology's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apex Biotechnology Cyclically Adjusted FCF per Share Chart

Apex Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.29 2.15 2.19 2.18 2.16

Apex Biotechnology Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.96 1.98 2.16 2.16 2.22

Competitive Comparison of Apex Biotechnology's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Apex Biotechnology's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Cyclically Adjusted Price-to-FCF falls into.



Apex Biotechnology Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Apex Biotechnology's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.425/131.7762*131.7762
=0.425

Current CPI (Mar. 2024) = 131.7762.

Apex Biotechnology Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.301 100.560 -0.394
201409 0.253 100.428 0.332
201412 1.836 99.070 2.442
201503 1.010 99.621 1.336
201506 0.434 100.684 0.568
201509 0.870 100.392 1.142
201512 1.948 99.792 2.572
201603 0.532 100.470 0.698
201606 0.137 101.688 0.178
201609 1.009 101.861 1.305
201612 0.615 101.863 0.796
201703 -0.767 102.862 -0.983
201706 -0.276 103.349 -0.352
201709 1.014 104.136 1.283
201712 0.361 104.011 0.457
201803 0.111 105.290 0.139
201806 -0.147 106.317 -0.182
201809 0.491 106.507 0.607
201812 -0.512 105.998 -0.637
201903 1.399 107.251 1.719
201906 0.106 108.070 0.129
201909 0.326 108.329 0.397
201912 1.801 108.420 2.189
202003 0.181 108.902 0.219
202006 0.898 108.767 1.088
202009 -0.459 109.815 -0.551
202012 1.464 109.897 1.755
202103 0.775 111.754 0.914
202106 0.708 114.631 0.814
202109 -0.452 115.734 -0.515
202112 0.350 117.630 0.392
202203 -0.465 121.301 -0.505
202206 0.884 125.017 0.932
202209 -0.479 125.227 -0.504
202212 -0.074 125.222 -0.078
202303 -0.461 127.348 -0.477
202306 1.240 128.729 1.269
202309 0.252 129.860 0.256
202312 1.027 129.419 1.046
202403 0.425 131.776 0.425

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Apex Biotechnology  (TPE:1733) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Apex Biotechnology's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=33.45/2.22
=15.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Apex Biotechnology was 18.66. The lowest was 8.21. And the median was 12.18.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Apex Biotechnology Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Apex Biotechnology's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Apex Biotechnology (TPE:1733) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp engages mainly in research, development, production, manufacturing and selling of biochemical testing instruments and its detection strips, and trade of products and components relevant to the core business. The company develops and markets biosensor-based blood glucose monitoring systems. The company manufactures non-invasive diagnostic technologies, IT-based telehealth care and molecular diagnostic and traditional Chinese medicine. Its product offerings include Eclipse plus multipurpose analyzer, Glucosure HT blood glucose monitoring system, HemoSmart GOLD hemoglobin screening system among others.

Apex Biotechnology (TPE:1733) Headlines

No Headlines